| **Characteristic** | **No. (%)** |
| --- | --- |
| **Total population** | 24 (100) |
| Mean age, years | 56.2 |
| Sex (%) |   |
| Male | 8 (33.3) |
| Female | 16 (66.7) |
| Primary diagnosis (%) |   |
|  Breast | 6 (25) |
|  Gastrointestinal | 2 (8.3) |
|  Lung | 2 (8.3) |
|  Genitourinary | 2 (8.3) |
|  Gynecologic | 5 (20.8) |
|  Head and neck | 4 (16.7) |
|  Others | 3 (12.6) |
| Stage (%) |  |
|  I | 4 (16.7) |
|  II | 5 (20.8) |
|  III | 7 (29.2) |
|  IV | 8 (33.3) |
| Stage at the beginning of the study (%) |   |
|  Local | 19 (79.2) |
|  Metastatic |  5 (20.8) |
| Stage at the time of third vaccine dose (%) |   |
|  Local | 11 (45.8) |
|  Metastatic | 13 (54.2) |
| Assessment of treatment response at the time of third vaccine dose (%)  |   |
|  No evidence of disease | 3 (12.5) |
|  Complete response | 8 (33.3) |
|  Stable disease | 4 (16.7) |
|  Partial response | 3 (12.5) |
|  Progressive disease | 6 (25) |
| Treatment (%) |   |
| Chemotherapy | 12 (50) |
| Immunotherapy | 6 (25) |
| Targeted therapy |  2 (8.3) |
| Chemotherapy plus targeted therapy | 0 (0) |
| Chemotherapy plus immunotherapy | 4 (16.7) |
| Immunotherapy plus targeted therapy | 0 (0) |
| Chemotherapy plus Immunotherapy plus targeted therapy  | 0 (0) |
| Heavily treated (three or more lines of treatment) at the time of third vaccine dose (%) |   |
| Yes | 9 (37.5) |
| No | 15 (63.5) |
| Prior/concomitant Radiotherapy (%) |   |
| Yes | 17 (70.8) |
| N | 7 (29.2) |
| Prior COVID-19 infection (%) |   |
| Yes | 1 (4.2) |
| No | 23 (95.8) |

**Supplementary Table 3.** Group 1 patient characteristics at third dose administration